These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35046733)

  • 1. Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies.
    Rogliani P; Calzetta L
    J Exp Pharmacol; 2022; 14():1-5. PubMed ID: 35046733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
    Gessner C; Kornmann O; Maspero J; van Zyl-Smit R; Krüll M; Salina A; Gupta P; Bostel S; Fucile S; Conde LG; Pfister P
    Respir Med; 2020; 170():106021. PubMed ID: 32843164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
    Brittain D; D'Andrea P; Gruen E; Hosoe M; Jain D; Jauernig J; Pethe A; Scosyrev E; Tanase AM; Tillmann HC
    Adv Ther; 2022 Jun; 39(6):2365-2378. PubMed ID: 35072888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
    van Zyl-Smit RN; Chapman KR; Kerstjens HAM; Gessner C; Sagara H; Tanase AM; Hosoe M; Pethe A; Lawrence D; Tillmann HC; D'Andrea P
    J Asthma Allergy; 2023; 16():123-134. PubMed ID: 36714049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
    van Zyl-Smit RN; Krüll M; Gessner C; Gon Y; Noga O; Richard A; de Los Reyes A; Shu X; Pethe A; Tanase AM; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):987-999. PubMed ID: 32653075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada.
    Mtibaa M; Gupta S; Muthukumar M; Marvel J; Kaur H; Ishikawa R; Olivenstein R
    Clinicoecon Outcomes Res; 2021; 13():957-967. PubMed ID: 34887668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
    Van Zyl-Smit RN; Kerstjens HA; Maspero JF; Kostikas K; Hosoe M; Tanase AM; D'Andrea P; Mezzi K; Brittain D; Lawrence D; Chapman KR
    Respir Med; 2023 May; 211():107172. PubMed ID: 36906187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.
    Sagara H; Barbier N; Ishii T; Yoshisue H; Nikolaev I; Hosoe M; Gon Y
    BMJ Open Respir Res; 2021 Mar; 8(1):. PubMed ID: 33737310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
    Scosyrev E; van Zyl-Smit R; Kerstjens H; Gessner C; Kornmann O; Jain D; Aubrun E; D'Andrea P; Hosoe M; Pethe A; Brittain D
    Respir Med; 2021; 180():106311. PubMed ID: 33711782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses.
    van Zyl-Smit RN; Kerstjens HAM; Maspero J; Tanase AM; Lawrence D; Mezzi K; D'Andrea P; Chapman KR
    Pulm Ther; 2023 Sep; 9(3):395-409. PubMed ID: 37526856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily, single-inhaler indacaterol/mometasone versus twice-daily salmeterol/fluticasone in Asian patients with inadequately controlled asthma:
    Gon Y; Ishii T; Lawrence D; Nikolaev I; Wang D; Sumi K; Nakamura Y
    J Asthma; 2022 Aug; 59(8):1627-1637. PubMed ID: 34346266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study.
    Kostikas K; Maspero JF; Chapman KR; Mezzi K; Jaumont X; Lawrence D; van Zyl-Smit R
    Respir Med; 2023 Oct; 217():107334. PubMed ID: 37392789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
    Chapman K; van Zyl-Smit R; Maspero J; Kerstjens HAM; Gon Y; Hosoe M; Tanase AM; Pethe A; Shu X; D'Andrea P
    BMJ Open Respir Res; 2021 Aug; 8(1):. PubMed ID: 34452934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
    Watz H; Hohlfeld JM; Singh D; Beier J; Diamant Z; Liu J; Hua S; Abd-Elaziz K; Pinot P; Jones I; Tillmann HC
    Respir Res; 2020 Apr; 21(1):87. PubMed ID: 32295593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
    Mangia PP; Gallo O; Ritrovato D; Pradelli L
    Clin Drug Investig; 2021 Sep; 41(9):785-794. PubMed ID: 34333742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma.
    Pelaia C; Crimi C; Crimi N; Ricciardi L; Scichilone N; Valenti G; Bonavita O; Andaloro S; Morini P; Rizzi A; Pelaia G
    Expert Rev Respir Med; 2022 Feb; 16(2):183-195. PubMed ID: 34845963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S; Vaidya S; Tillmann HC; Sakita Y; Machineni S; Heudi O; Furihata K
    BMC Pulm Med; 2021 Jan; 21(1):18. PubMed ID: 33413291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
    Sagara H; D'Andrea P; Tanase AM; Pethe A; Tanaka Y; Matsuo K; Hosoe M; Nakamura Y
    J Asthma; 2023 Feb; 60(2):403-411. PubMed ID: 35348408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways.
    Rogliani P; Ritondo BL; Facciolo F; Matera MG; Nikolaev I; Calzetta L
    Pharmacol Res; 2021 Oct; 172():105801. PubMed ID: 34363950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.